哥伦比亚亚马逊地区无并发症间日疟原虫疟疾患者对氯喹-伯氨喹的治疗反应和安全性。

IF 2.4 3区 医学 Q3 INFECTIOUS DISEASES
Paula Calderón-Ruiz, Gabriel Velez-Tobón, Sebastian Bolívar-Hernández, Luz Mila Murcia-Montaño, Alberto Tobón-Castaño
{"title":"哥伦比亚亚马逊地区无并发症间日疟原虫疟疾患者对氯喹-伯氨喹的治疗反应和安全性。","authors":"Paula Calderón-Ruiz, Gabriel Velez-Tobón, Sebastian Bolívar-Hernández, Luz Mila Murcia-Montaño, Alberto Tobón-Castaño","doi":"10.1186/s12936-024-05170-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In Colombia, published studies on the treatment of uncomplicated Plasmodium vivax malaria with chloroquine-primaquine are scarce. The aim of this study was to evaluate the therapeutic response to two treatment regimens at the 28-day follow-up and the occurrence of adverse events in patients with P. vivax malaria.</p><p><strong>Methods: </strong>A quasi-experimental clinical trial was conducted at 3 sites in the Department of Amazonas. Patients received supervised or unsupervised anti-malarial treatment (chloroquine plus primaquine), and the primary effectiveness endpoint was the clinical and parasitological response. Safety was assessed through adverse event surveillance.</p><p><strong>Results: </strong>A total of 103 patients were included: 53 in the 7-day primaquine group (Group I) and 50 in the group receiving primaquine for 14 days (Group II). Among the patients in group I, an adequate treatment response of 100% and 89.5% was found in patients who received supervised and unsupervised treatment, respectively. In Group II, adequate responses of 100% and 95% were reported for patients who received supervised and unsupervised treatment, respectively. No adverse events were detected.</p><p><strong>Conclusions: </strong>The response to combined treatment with chloroquine plus primaquine continues to be adequate for treating P. vivax malaria in the Colombian Amazon region; however, a response to unsupervised treatment in the region is recommended.</p>","PeriodicalId":18317,"journal":{"name":"Malaria Journal","volume":"23 1","pages":"348"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575219/pdf/","citationCount":"0","resultStr":"{\"title\":\"Chloroquine-primaquine therapeutic response and safety in patients with uncomplicated Plasmodium vivax malaria in the Colombian Amazon region.\",\"authors\":\"Paula Calderón-Ruiz, Gabriel Velez-Tobón, Sebastian Bolívar-Hernández, Luz Mila Murcia-Montaño, Alberto Tobón-Castaño\",\"doi\":\"10.1186/s12936-024-05170-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In Colombia, published studies on the treatment of uncomplicated Plasmodium vivax malaria with chloroquine-primaquine are scarce. The aim of this study was to evaluate the therapeutic response to two treatment regimens at the 28-day follow-up and the occurrence of adverse events in patients with P. vivax malaria.</p><p><strong>Methods: </strong>A quasi-experimental clinical trial was conducted at 3 sites in the Department of Amazonas. Patients received supervised or unsupervised anti-malarial treatment (chloroquine plus primaquine), and the primary effectiveness endpoint was the clinical and parasitological response. Safety was assessed through adverse event surveillance.</p><p><strong>Results: </strong>A total of 103 patients were included: 53 in the 7-day primaquine group (Group I) and 50 in the group receiving primaquine for 14 days (Group II). Among the patients in group I, an adequate treatment response of 100% and 89.5% was found in patients who received supervised and unsupervised treatment, respectively. In Group II, adequate responses of 100% and 95% were reported for patients who received supervised and unsupervised treatment, respectively. No adverse events were detected.</p><p><strong>Conclusions: </strong>The response to combined treatment with chloroquine plus primaquine continues to be adequate for treating P. vivax malaria in the Colombian Amazon region; however, a response to unsupervised treatment in the region is recommended.</p>\",\"PeriodicalId\":18317,\"journal\":{\"name\":\"Malaria Journal\",\"volume\":\"23 1\",\"pages\":\"348\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575219/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Malaria Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12936-024-05170-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Malaria Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12936-024-05170-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:在哥伦比亚,有关氯喹-伯氨喹治疗无并发症间日疟原虫疟疾的公开研究很少。本研究旨在评估两种治疗方案在 28 天随访期间的治疗反应以及间日疟原虫疟疾患者不良反应的发生情况:在亚马孙省的 3 个地点开展了一项准实验性临床试验。患者接受有监督或无监督的抗疟治疗(氯喹加伯氨喹),主要疗效终点是临床和寄生虫学反应。安全性通过不良事件监测进行评估:共纳入 103 名患者:结果:共纳入103名患者:53名患者接受为期7天的伯氨喹治疗(I组),50名患者接受为期14天的伯氨喹治疗(II组)。在 I 组患者中,接受监督治疗和非监督治疗的患者的充分治疗反应分别为 100%和 89.5%。在第二组中,接受监督治疗和未接受监督治疗的患者的充分治疗反应分别为 100%和 95%。未发现任何不良反应:结论:在哥伦比亚亚马逊地区,氯喹加伯氨喹联合治疗的反应仍足以治疗间日疟原虫性疟疾;不过,建议该地区的患者接受无监督治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Chloroquine-primaquine therapeutic response and safety in patients with uncomplicated Plasmodium vivax malaria in the Colombian Amazon region.

Background: In Colombia, published studies on the treatment of uncomplicated Plasmodium vivax malaria with chloroquine-primaquine are scarce. The aim of this study was to evaluate the therapeutic response to two treatment regimens at the 28-day follow-up and the occurrence of adverse events in patients with P. vivax malaria.

Methods: A quasi-experimental clinical trial was conducted at 3 sites in the Department of Amazonas. Patients received supervised or unsupervised anti-malarial treatment (chloroquine plus primaquine), and the primary effectiveness endpoint was the clinical and parasitological response. Safety was assessed through adverse event surveillance.

Results: A total of 103 patients were included: 53 in the 7-day primaquine group (Group I) and 50 in the group receiving primaquine for 14 days (Group II). Among the patients in group I, an adequate treatment response of 100% and 89.5% was found in patients who received supervised and unsupervised treatment, respectively. In Group II, adequate responses of 100% and 95% were reported for patients who received supervised and unsupervised treatment, respectively. No adverse events were detected.

Conclusions: The response to combined treatment with chloroquine plus primaquine continues to be adequate for treating P. vivax malaria in the Colombian Amazon region; however, a response to unsupervised treatment in the region is recommended.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Malaria Journal
Malaria Journal 医学-寄生虫学
CiteScore
5.10
自引率
23.30%
发文量
334
审稿时长
2-4 weeks
期刊介绍: Malaria Journal is aimed at the scientific community interested in malaria in its broadest sense. It is the only journal that publishes exclusively articles on malaria and, as such, it aims to bring together knowledge from the different specialities involved in this very broad discipline, from the bench to the bedside and to the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信